{"filing":{"accession_number":"0001654954-26-008476","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-09-21","report_date":"2026-09-21","primary_document":"a4447v.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426008476/a4447v.htm"},"events":[{"id":33848,"run_id":31151,"accession_number":"0001654954-26-008476","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The 6-K discloses a positive Committee for Medicinal Products for Human Use (CHMP) recommendation for approval of Enhertu (trastuzumab deruxtecan) in the EU as adjuvant treatment for HER2-positive early breast cancer with residual disease. This is a material regulatory milestone for a key oncology product—the DESTINY-Breast05 trial showed 53% risk reduction in invasive disease recurrence or death versus the current standard of care (T-DM1). While not a discrete M\u0026A, financial, or governance event, this regulatory advancement represents a significant operational and commercial milestone that would affect a reasonable investor's assessment of the company's pipeline and market opportunities.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-21","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":37404,"accession_number":"0001654954-26-008476","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The 6-K discloses a positive Committee for Medicinal Products for Human Use (CHMP) recommendation for approval of Enhertu (trastuzumab deruxtecan) in the EU as adjuvant treatment for HER2-positive early breast cancer with residual disease. This is a material regulatory milestone for a key oncology product—the DESTINY-Breast05 trial showed 53% risk reduction in invasive disease recurrence or death versus the current standard of care (T-DM1). While not a discrete M\u0026A, financial, or governance event, this regulatory advancement represents a significant operational and commercial milestone that would affect a reasonable investor's assessment of the company's pipeline and market opportunities.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-21T10:51:41.849727+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-21"}]}